ARDX Logo

Ardelyx, Inc. (ARDX) 

NASDAQ
Market Cap
$1.53B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
445 of 776
Rank in Industry
233 of 433

Largest Insider Buys in Sector

ARDX Stock Price History Chart

ARDX Stock Performance

About Ardelyx, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing …

Insider Activity of Ardelyx, Inc.

Over the last 12 months, insiders at Ardelyx, Inc. have bought $0 and sold $13.2M worth of Ardelyx, Inc. stock.

On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $752,636 and sold $5.21M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 567,000 shares for transaction amount of $1M was made by MOTT DAVID M (director) on 2022‑11‑17.

List of Insider Buy and Sell Transactions, Ardelyx, Inc.

2024-10-28SalePresident & CEO
25,000
0.0109%
$5.91$147,740-1.00%
2024-10-11SalePresident & CEO
7,500
0.003%
$6.01$45,075-2.48%
2024-09-27SaleChief Development Officer
49,564
0.0229%
$6.92$342,983-9.92%
2024-09-26SalePresident & CEO
3,000
0.0013%
$6.07$18,210+4.78%
2024-09-13SaleChief Development Officer
5,312
0.0022%
$6.26$33,254-4.91%
2024-09-11SalePresident & CEO
35,000
0.0147%
$5.61$196,3990.00%
2024-08-27SalePresident & CEO
7,500
0.0032%
$6.22$46,635-3.70%
2024-08-20SalePresident & CEO
32,225
0.0131%
$5.86$188,848-1.31%
2024-08-20SaleSee Remarks
4,969
0.002%
$5.86$29,120-1.31%
2024-08-20SaleChief Medical Officer
7,412
0.003%
$5.86$43,437-1.31%
2024-08-20SaleChief Financial Officer
5,289
0.0022%
$5.86$30,995-1.31%
2024-08-20SaleSee Remarks
7,089
0.0029%
$5.86$41,544-1.31%
2024-08-20SaleChief Development Officer
20,507
0.0085%
$6.00$123,042-1.31%
2024-08-20SaleChief Development Officer
27,726
0.0115%
$5.96$165,348-1.31%
2024-08-20SaleChief Development Officer
7,219
0.0029%
$5.86$42,306-1.31%
2024-08-20SaleSee Remarks
3,567
0.0015%
$5.86$20,904-1.31%
2024-08-16SaleChief Development Officer
20,000
0.0087%
$5.94$118,740+1.09%
2024-08-12SalePresident & CEO
1,229
0.0005%
$5.71$7,018+3.78%
2024-07-29SalePresident & CEO
30,000
0.013%
$5.64$169,314+7.91%
2024-07-15SalePresident & CEO
7,500
0.0031%
$5.97$44,7680.00%

Insider Historical Profitability

37.65%
RAAB MICHAELPresident & CEO
1210108
0.5109%
$6.44148+247.57%
Williams Laura AChief Medical Officer
314740
0.1329%
$6.44113+247.57%
Rosenbaum David P.Chief Development Officer
301946
0.1275%
$6.44152+247.57%
Renz Justin AChief Financial Officer
295257
0.1247%
$6.44118+247.57%
GRAMMER ELIZABETH ASee Remarks
192380
0.0812%
$6.44239+116.79%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Janus Henderson$160.86M9.4222.05M-10.59%-$19.05M0.08
BlackRock$124.8M7.3117.1M+1.91%+$2.34M<0.01
State Street$102.85M6.0214.09M-17.62%-$22M<0.01
The Vanguard Group$97.76M5.7213.39M+2.81%+$2.67M<0.01
Eventide Asset Management$49.73M2.916.81M+0.11%+$54,560.200.8
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.